Blog Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?

The pharmaceutical and manufacturing industries have undergone significant changes in recent years. In a move to take advantage of their market dominance and the exclusivity of their drugs, Novo Nordisk has acquired Catalent, a contract drug manufacturer with substantial production capacity. This acquisition has the potential to trigger several other billion-dollar deals in the near future and shows the possibility that:

"We are entering a new era of pharmaceutical business where it is faster to find a new drug candidate than it is to build up a production infrastructure to capitalize on it.”

Sergey Jakimov, a managing partner at LongeVC, has shared more in the Labiotech article. Read the full piece here.